Millennium Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-866,152
| Closed | -$3.64M | – | 7146 |
|
|
2023
Q1 | $3.64M | Sell |
866,152
-3,896,617
| -82% | -$20.2M | ﹤0.01% | 2896 |
|
|
2022
Q4 | $28.6M | Buy |
4,762,769
+8,641
| +0.2% | +$47.2K | 0.02% | 1149 |
|
|
2022
Q3 | $27.7M | Buy |
4,754,128
+1,586,041
| +50% | +$9.88M | 0.02% | 1061 |
|
|
2022
Q2 | $18.9M | Buy |
3,168,087
+989,524
| +45% | +$5.07M | 0.01% | 1376 |
|
|
2022
Q1 | $10.2M | Buy |
2,178,563
+1,972,416
| +957% | +$5.88M | 0.01% | 2150 |
|
|
2021
Q4 | $511K | Sell |
206,147
-148,952
| -42% | -$364K | ﹤0.01% | 5023 |
|
|
2021
Q3 | $1.05M | Buy |
355,099
+70,883
| +25% | +$193K | ﹤0.01% | 4627 |
|
|
2021
Q2 | $711K | Sell |
284,216
-151,384
| -35% | -$363K | ﹤0.01% | 4975 |
|
|
2021
Q1 | $1.27M | Buy |
435,600
+53,545
| +14% | +$175K | ﹤0.01% | 3986 |
|
|
2020
Q4 | $1.23M | Buy |
+382,055
| New | +$1.27M | ﹤0.01% | 3593 |
|
|
2020
Q3 | – | Sell |
-60,798
| Closed | -$71K | – | 5073 |
|
|
2020
Q2 | $71K | Buy |
60,798
+24,018
| +65% | +$25.4K | ﹤0.01% | 4022 |
|
|
2020
Q1 | $34K | Buy |
36,780
+25,904
| +238% | +$29.7K | ﹤0.01% | 3703 |
|
|
2019
Q4 | $17K | Sell |
10,876
-207,608
| -95% | -$197K | ﹤0.01% | 4132 |
|
|
2019
Q3 | $181K | Sell |
218,484
-471,067
| -68% | -$360K | ﹤0.01% | 3818 |
|
|
2019
Q2 | $593K | Buy |
+689,551
| New | +$637K | ﹤0.01% | 3107 |
|
|
2018
Q3 | – | Sell |
-676,755
| Closed | -$3.37M | – | 4556 |
|
|
2018
Q2 | $3.37M | Sell |
676,755
-109,828
| -14% | -$481K | ﹤0.01% | 2059 |
|
|
2018
Q1 | $3.07M | Buy |
+786,583
| New | +$2.77M | ﹤0.01% | 2089 |
|
|
2017
Q4 | – | Sell |
-67,352
| Closed | -$215K | – | 4319 |
|
|
2017
Q3 | $215K | Buy |
+67,352
| New | +$225K | ﹤0.01% | 3209 |
|
|
2017
Q2 | – | Sell |
-159,120
| Closed | -$668K | – | 4198 |
|
|
2017
Q1 | $668K | Buy |
159,120
+114,070
| +253% | +$527K | ﹤0.01% | 2631 |
|
|
2016
Q4 | $184K | Sell |
45,050
-23,580
| -34% | -$97.8K | ﹤0.01% | 3103 |
|
|
2016
Q3 | $257K | Sell |
68,630
-217,554
| -76% | -$792K | ﹤0.01% | 2878 |
|
|
2016
Q2 | $973K | Buy |
286,184
+193,816
| +210% | +$889K | ﹤0.01% | 2184 |
|
|
2016
Q1 | $491K | Buy |
+92,368
| New | +$738K | ﹤0.01% | 2522 |
|
|
2015
Q4 | – | Sell |
-51,198
| Closed | -$747K | – | 4100 |
|
|
2015
Q3 | $747K | Sell |
51,198
-60,573
| -54% | -$1.05M | ﹤0.01% | 2448 |
|
|
2015
Q2 | $2.18M | Sell |
111,771
-384,475
| -77% | -$7.42M | ﹤0.01% | 1862 |
|
|
2015
Q1 | $8.98M | Buy |
496,246
+449,095
| +952% | +$10.1M | 0.02% | 1075 |
|
|
2014
Q4 | $1.11M | Buy |
47,151
+45,791
| +3,367% | +$1.06M | ﹤0.01% | 2412 |
|
|
2014
Q3 | $33K | Sell |
1,360
-34,419
| -96% | -$895K | ﹤0.01% | 3622 |
|
|
2014
Q2 | $1M | Buy |
+35,779
| New | +$1.08M | ﹤0.01% | 2199 |
|
|
2013
Q3 | – | Sell |
-1,635
| Closed | -$17K | – | 3840 |
|
|
2013
Q2 | $17K | Buy |
+1,635
| New | +$19.2K | ﹤0.01% | 2935 |
|
Other funds holding CTIC
Millennium Management's CTIC Position: Q2 2023 in Review
Millennium Management sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 866,152 shares — an estimated $3.64M sold.
Millennium Management first reported a position in CTIC in Q2 2013 and held it in 30 quarters. The position peaked at $28.6M in Q4 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.
- Millennium Management reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
- Millennium Management sold 866,152 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $3.64M.
- Millennium Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2013 and held it in 30 quarters.
- Millennium Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $28.6M in Q4 2022.
- 2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.
Based on Millennium Management's 13F filing for Q2 2023, filed 14 Aug 2023.